Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicenter study

INTRODUCTION: HER2 mutations occur in 1-3% of lung adenocarcinomas. With increasing use of next-generation sequencing at diagnosis, more patients with HER2-mutant tumors are presenting for treatment. Few data are available to describe the clinical course and outcomes of these patients when treated w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur J Cancer
Главные авторы: Lai, W. Victoria, Lebas, Louisiane, Barnes, Tristan A., Milia, Julie, Ni, Ai, Gautschi, Oliver, Peters, Solange, Ferrara, Roberto, Plodkowski, Andrew J., Kavanagh, John, Sabari, Joshua K., Clarke, Stephen J., Pavlakis, Nick, Drilon, Alexander, Rudin, Charles M., Arcila, Maria E., Leighl, Natasha B., Shepherd, Frances A., Kris, Mark G., Mazières, Julien, Li, Bob T.
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6426688/
https://ncbi.nlm.nih.gov/pubmed/30685684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2018.11.030
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы